Charles River Laboratories International (NYSE:CRL) Rating Lowered to Hold at Wall Street Zen

Charles River Laboratories International (NYSE:CRL - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Saturday.

Several other equities research analysts have also recently weighed in on CRL. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Barclays raised their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a research report on Wednesday, May 14th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, twelve have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Stock Down 0.2%

Shares of Charles River Laboratories International stock opened at $157.12 on Friday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International has a 52-week low of $91.86 and a 52-week high of $254.15. The company's 50 day moving average price is $140.70 and its 200-day moving average price is $152.71. The stock has a market capitalization of $7.72 billion, a price-to-earnings ratio of -241.72, a P/E/G ratio of 5.32 and a beta of 1.49.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. During the same quarter last year, the firm earned $2.27 EPS. The company's revenue was down 2.7% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International will post 9.36 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the sale, the executive vice president directly owned 19,513 shares of the company's stock, valued at $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Charles River Laboratories International

Several hedge funds have recently added to or reduced their stakes in the stock. Rothschild Investment LLC raised its position in shares of Charles River Laboratories International by 480.0% in the 1st quarter. Rothschild Investment LLC now owns 174 shares of the medical research company's stock worth $26,000 after purchasing an additional 144 shares during the last quarter. Brooklyn Investment Group increased its stake in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company's stock valued at $27,000 after purchasing an additional 86 shares in the last quarter. HM Payson & Co. purchased a new position in Charles River Laboratories International in the first quarter worth about $31,000. Optiver Holding B.V. bought a new position in shares of Charles River Laboratories International in the fourth quarter worth approximately $37,000. Finally, GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after buying an additional 190 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.